Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
The MIGHT Trial: IVIG in Anti-HMGCR Immune Mediated Necrotizing Myopathy
NCT06599697Phase 2Recruiting
- Sponsor
- University of Alabama at Birmingham
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of intravenous immunoglobulin G in Anti-HMGCR immune-mediated necrotizing myopathy (HMGCR-IMNM), sponsored by University of Alabama at Birmingham. Started Oct 2025; status: recruiting.
02
Drugs
intravenous immunoglobulin G
03
Conditions
Anti-HMGCR immune-mediated necrotizing myopathy (HMGCR-IMNM)
Beyond the preview
Go deeper on NCT06599697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06599697.